We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Radcal IBA  Group

Download Mobile App




Machine Learning Model Uses MRI Data to Identify Candidates for Liver Transplant

By MedImaging International staff writers
Posted on 22 Aug 2022
Image: Machine learning models can predict hepatocellular carcinoma treatment response (Photo courtesy of Pexels)
Image: Machine learning models can predict hepatocellular carcinoma treatment response (Photo courtesy of Pexels)

Post-treatment recurrence is an unpredictable complication after liver transplant for hepatocellular carcinoma (HCC) that is associated with poor survival. Biomarkers are needed to estimate recurrence risk before organ allocation. A new study has found that machine learning (ML) models applied to presently underutilized imaging features could help construct more reliable criteria for organ allocation and liver transplant eligibility.

In the proof-of-concept study, researchers at Yale University School of Medicine (New Haven, CT, USA) evaluated the use of ML to predict recurrence from pretreatment laboratory, clinical, and MRI data in patients with early-stage HCC initially eligible for liver transplant. The study included 120 patients (88 men, 32 women; median age, 60 years) diagnosed with early-stage HCC between June 2005 and March 2018, who were initially eligible for liver transplant and underwent treatment by transplant, resection, or thermal ablation. Patients underwent pretreatment MRI and post-treatment imaging surveillance, and imaging features were extracted from post-contrast phases of pretreatment MRI examinations using a pre-trained convolutional neural network (VGG-16). Pretreatment clinical characteristics (including laboratory data) and extracted imaging features were integrated to develop three ML models - clinical, imaging, combined - for recurrence prediction within 1-6 years post-treatment.

Ultimately, all three models predicted post-treatment recurrence for early-stage HCC from pretreatment clinical (AUC 0.60–0.78, across all six time frames), MRI (AUC 0.71–0.85), and both data combined (AUC 0.62–0.86). Using imaging data as the sole model input yielded higher predictive performance than clinical data alone; however, combining both data types did not significantly improve performance over use of imaging data alone.

“The findings suggest that machine learning-based models can predict recurrence before therapy allocation in patients with early-stage HCC initially eligible for liver transplant,” wrote corresponding author Julius Chapiro from the department of radiology and biomedical imaging at Yale University School of Medicine.

Related Links:

Yale University School of Medicine

Biopsy Software
Affirm® Contrast
Post-Processing Imaging System
DynaCAD Prostate
Half Apron
Demi
Multi-Use Ultrasound Table
Clinton

Channels

Nuclear Medicine

view channel
Image: A bone cancer cell showing supportive fibers (in red), genetic material (in blue), and the specific target protein LRRC15 (in green) (Photo courtesy of Ulmert Laboratory)

Radiotheranostic Approach Detects, Kills and Reprograms Aggressive Cancers

Aggressive cancers such as osteosarcoma and glioblastoma often resist standard therapies, thrive in hostile tumor environments, and recur despite surgery, radiation, or chemotherapy. These tumors also... Read more

Imaging IT

view channel
Image: The new Medical Imaging Suite makes healthcare imaging data more accessible, interoperable and useful (Photo courtesy of Google Cloud)

New Google Cloud Medical Imaging Suite Makes Imaging Healthcare Data More Accessible

Medical imaging is a critical tool used to diagnose patients, and there are billions of medical images scanned globally each year. Imaging data accounts for about 90% of all healthcare data1 and, until... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.